Knight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distribution, and Supply Agreement for Akynzeo® and Aloxi®
12 Maio 2022 - 8:00AM
Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American
(ex-USA) specialty pharmaceutical company, and Helsinn Healthcare
SA (“Helsinn”), a fully integrated, global biopharma company with a
diversified pipeline of innovative oncology assets and strong track
record of commercial execution, today announced that Knight,
through one of its wholly-owned subsidiaries, and Helsinn have
entered into an exclusive license, distribution and supply
agreement for AKYNZEO® oral/IV (netupitant/palonosetron /
fosnetupitant/palonosetron) in Canada, Brazil, Argentina, Uruguay
and Paraguay, and ALOXI® oral/IV (palonosetron) in Canada (the
“Products”). According to IQVIA, sales of AKYNZEO® in Canada and
Brazil were approximately $7 million in 2021.
Under the terms of the agreement, Knight shall
have the exclusive right to distribute, promote, market and sell
the Products in the licensed territories. Knight will begin
commercial activities following a transition period from Helsinn’s
current licensees.
“We are very excited to enter into this
agreement with Helsinn for AKYNZEO® in Canada, Brazil and other
selected Latin American countries, and ALOXI® in Canada,” said
Samira Sakhia, President and CEO of Knight. “These products are
highly synergistic with our oncology portfolio and commercial
footprint, and we look forward to widening access to these
therapies in our target markets. AKYNZEO® and ALOXI® are leading,
guideline-recommended1,2,3 antiemetics that help to prevent one of
the most common side effects of chemotherapy.”
“AKYNZEO® and ALOXI® form a key part of
Helsinn’s commercial engine of supportive cancer care products,”
said Giorgio Calderari, Helsinn CEO. “Knight has a unique footprint
with strong capabilities across Canada and Latin America, and we
look forward to collaborating with them as they work to ensure
patients in these geographies have access to these important
medicines.”
The financial terms of the transaction were not
disclosed.
About
Akynzeo®AKYNZEO® is the first and only
5-HT3 and NK1 receptor antagonist fixed combination approved for
the prevention of chemotherapy-induced acute and delayed nausea and
vomiting. A single dose of AKYNZEO® given with dexamethasone has
been shown to prevent chemotherapy-induced nausea and vomiting for
up to 5 days. AKYNZEO® oral is approved and marketed in Canada for
the prevention of acute and delayed nausea and vomiting associated
with highly emetogenic cancer chemotherapy and the prevention of
acute nausea and vomiting associated with moderately emetogenic
cancer therapy that is uncontrolled by a 5-HT3 receptor antagonist
alone in adults. AKYNZEO® oral is also approved and marketed in
Argentina and Brazil for the prevention of acute and delayed nausea
and vomiting associated with highly emetogenic cisplatin-based
cancer chemotherapy and prevention of acute and delayed nausea and
vomiting associated with moderately emetogenic cancer chemotherapy
in adults.
About
Aloxi®ALOXI® is a second generation 5-HT3
receptor antagonist with high receptor binding affinity and a
duration of action up to 5 days after chemotherapy
administration4,5. ALOXI® solution for injection is approved and
marketed in Canada for the prevention of acute and delayed nausea
and vomiting associated with moderately emetogenic cancer
chemotherapy and highly emetogenic cancer chemotherapy, including
high dose cisplatin in adults. In Canada, the product is also
indicated in pediatric patients aged 2 to 17 years for the
prevention of acute nausea and vomiting associated with moderately
and highly emetogenic cancer chemotherapy. ALOXI® oral is approved
in Canada for use in adults for the prevention of acute nausea and
vomiting associated with moderately emetogenic cancer
chemotherapy.
References1 Roila F. et al. Ann Oncol. 2016
Sep;27(suppl 5):v119-v133. MASCC/ESMO Antiemetic Guideline 2016
V.1.4 last update July 2019. Available at: http://www.mascc.org/;2
Hesketh J. et al. J Clin Oncol. 2020 Aug 20;38(24):2782-2797. doi:
10.1200/JCO.20.01296. Epub 2020 Jul 13;3 NCCN: National
Comprehensive Cancer Network; NCCN Clinical Practice Guidelines in
Oncology; Version 2.2022. Available at: www.nccn.org4 Rojas C,
Slusher BS. Eur J Pharmacol 2012;684(1-3):1-7; 6;5 Navari RM and
Aapro M. N Engl J Med 2016;374:1356-67.
About Knight Therapeutics
Inc.
Knight Therapeutics Inc., headquartered in
Montreal, Canada, is a specialty pharmaceutical company focused on
acquiring or in-licensing and commercializing pharmaceutical
products for Canada and Latin America. Knight owns Biotoscana
Investments S.A., a pan-Latin American specialty pharmaceutical
company. Knight’s Latin American subsidiaries operate under United
Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics
Inc.'s shares trade on TSX under the symbol GUD. For more
information about Knight Therapeutics Inc., please visit the
company's web site at www.gud-knight.com or
www.sedar.com.
Forward-Looking Statements for Knight
Therapeutics Inc.
This document contains forward-looking
statements for Knight Therapeutics Inc. and its subsidiaries. These
forward-looking statements, by their nature, necessarily involve
risks and uncertainties that could cause actual results to differ
materially from those contemplated by the forward-looking
statements. Knight Therapeutics Inc. considers the assumptions on
which these forward-looking statements are based to be reasonable
at the time they were prepared but cautions the reader that these
assumptions regarding future events, many of which are beyond the
control of Knight Therapeutics Inc. and its subsidiaries, may
ultimately prove to be incorrect. Factors and risks, which could
cause actual results to differ materially from current expectations
are discussed in Knight Therapeutics Inc.'s Annual Report and in
Knight Therapeutics Inc.'s Annual Information Form for the year
ended December 31, 2021 as filed on www.sedar.com. Knight
Therapeutics Inc. disclaims any intention or obligation to update
or revise any forward-looking statements whether because of new
information or future events, except as required by law.
About Helsinn
Helsinn is a fully integrated, global biopharma
company headquartered in Lugano, Switzerland. It is focused on
improving the lives of cancer patients all over the world with a
leading position in cancer supportive care and an innovative
pipeline of cancer therapeutics.
Helsinn is a third-generation family-owned
company, that since 1976 has been focused on improving the lives of
patients, guided by core values of respect, integrity and quality.
It operates a unique licensing business model with integrated drug
development and manufacturing capabilities. Helsinn has a
commercial presence in 190 countries either directly, with
operating subsidiaries in the U.S. and China, or via its network of
long-standing trusted partners. Helsinn also has a fully integrated
supply chain and product development through its subsidiary in
Ireland, Helsinn Birex Pharmaceuticals Ltd.
Helsinn plays an active and central role in
promoting social transformation in favor of people and the
environment. Corporate social responsibility is at the heart of
everything we do, which is reinforced in the company’s strategic
plan by a commitment to sustainable growth.
For more information, please visit www.Helsinn.com and follow us
on Twitter and LinkedIn.
For more information: Helsinn Media
Contact:Paola Bonvicini Group Head of Communication
Lugano, Switzerland Tel: +41 (0) 91 985 21 21 Email:
Info-hhc@helsinn.comFor more information, please visit
www.helsinn.com and follow us on Twitter and LinkedIn
Investor Contact for Knight Therapeutics
Inc.:
Knight Therapeutics Inc. |
Samira SakhiaPresident & Chief Executive OfficerT:
514.484.4483F: 514.481.4116Email: info@knighttx.comWebsite:
www.gud-knight.com |
Arvind UtchanahChief Financial OfficerT. 598.2626.2344Email:
info@knighttx.comWebsite: www.gud-knight.com |
Knight Therapeutics (TSX:GUD)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Knight Therapeutics (TSX:GUD)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024